XNW28012

Evopoint Biosciences Inc. · Phase 1 active Small molecule

At a glance

Generic name	XNW28012
Sponsor	Evopoint Biosciences Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

XNW28012 CI brief — competitive landscape report
XNW28012 updates RSS · CI watch RSS
Evopoint Biosciences Inc. portfolio CI